CAR-T,

Ying Li1, Zhenhua Hu2, Yuanyuan Li3,4,5

  • 1Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

PubMed
概括

化学抗原受体-T (CAR-T) 细胞疗法对血液癌症具有前景,但面临制造,有效性和安全性的障碍. 诸如通用CAR-T细胞和体内诱导等策略旨在克服这些挑战,以实现更广泛的临床应用.

相关概念视频